IFDCTN
The International Federation of Dermatology Clinical Trials Networks
University of Nottingham
  • Print
  

The aims of the IFDCTN are to:

  • Promote international collaboration in dermatology clinical trials.
  • Improve the standard of the design and reporting of dermatology clinical trials across the globe.
  • Encourage the establishment of local dermatology clinical trials networks.
  • Act as a resource to assist with the above.
  • To develop as innovations in methodology become available, meeting new requirements for knowledge. 
Hywel466x335edit

About the 
Federation 

Professor Hywel Williams, Chair of IFDCTN
 
 

Why independent?

The IFDCTN is geared towards non-commercial clinical trials, though this doesn't mean we are against industry-led trials. Our reasons for focussing on non-commercial research is threefold:

 

1. Industry already does things well

The larger drug companies are professional, well organized and have a good understanding of designing, conducting, monitoring, delivering and reporting clinical trials.
 

 

2. The need to tackle the questions that industry does not address for commercial reasons

For example, novel uses of existing inexpensive drugs, such as prednisolone, where there is financial motive to show that it works, or by investigating interventions for rare skin diseases, where little money is to be made.

It is also important that non-pharmacological approaches such as educational interventions are tested in clinical dermatology, as the answer to many problems is not only drugs.

 

3. The need to build an international community of dermatology health care professionals

They will then be in a better position to influence and input into the design, delivery and dissemination of good clinical research.

Not only will this approach help democratise clinical dermatology research by involving those from less developed countries, it will also help to educate larger numbers of people on the importance of critical appraisal, good quality reporting and changing clinical practice to improve the welfare of patients as new reliable evidence becomes available.

 

Steering committee

The chair of the IFDCTN is Professor Hywel Williams,  based at the Centre of Evidence Based Dermatology (CEBD) at The University of Nottingham, UK. 

Why international?

The aim of the IFDCTN is to share information in the hope of improving standards in conducting and reporting dermatology clinical trials.

Global knowledge

The potential benefit to patients can only be reliably estimated through reviews of all relevant studies, conducted across the world. 

There is therefore a vested interest in ensuring that evidence can be successfully used in such systematic reviews and not discarded because of missing data or a fundamental flaw in design. 

It is for this reason that the potential benefit of a patient with severe atopic eczema in Nottingham, can depend on information from a clinical trial in Buenos Aires or Manilla. 

Universal knowledge on the effects of treatments requires usable information from all global studies.  

 

 

IFDCTN

telephone: (0)115 846 8621
fax: (0)115 846 8618

Email: IFDCTN@nottingham.ac.uk